Vivos Therapeutics (NASDAQ: VVOS) reported Q3 EPS of ($0.49), $0.01 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $4.97 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.